Philly Pharmacy's Messy Logs End DEA Registration
Published Date: 7/14/2025
Notice
Summary
Just Here II Pharmacy in Philadelphia lost its DEA registration because it didn’t keep proper records of controlled substances, making it unsafe for the public. The pharmacy’s registration was suspended immediately and then officially revoked by the DEA, even though their registration expired at the end of 2024. This means Just Here II can no longer handle controlled drugs, protecting community safety.
Analyzed Economic Effects
2 provisions identified: 1 benefits, 1 costs, 0 mixed.
DEA Revokes Pharmacy Registration
Just Here II Pharmacy (DEA Certificate No. FJ1928689) had its DEA registration suspended on October 24, 2024 and the DEA issued a final order revoking the registration. The revocation bars the pharmacy from handling controlled substances and also denies any pending renewal, modification, or other registration applications for Just Here II in Pennsylvania; the Order is effective August 13, 2025.
Revocation Intended to Protect Public
If you live in Pennsylvania, the DEA found large discrepancies in Just Here II Pharmacy's controlled-substance records (for example: ~200 units of oxycodone 5 mg; ~1,459 units of oxycodone 15 mg; ~2,044 units of alprazolam 1 mg; ~2,930 units of alprazolam 2 mg; and ~2,839 units of promethazine with codeine) and revoked the registration to protect public health and safety. The DEA described variances for listed substances ranging from about 33% to 100% and made the revocation effective August 13, 2025.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-11526 — Implementation of the Substance Use-Disorder Prevention That Promotes Opioid Recovery and Treatment for Patients and Communities Act of 2018: Dispensing and Administering Controlled Substances for Medication-Assisted Treatment
Starting July 9, 2026, new rules make it easier for doctors and pharmacies to provide medicine that helps people recover from opioid addiction. These changes affect healthcare providers by expanding who can give medication-assisted treatment and how pharmacies can deliver these medicines. The goal? Faster, safer access to treatment with clear rules that save time and support recovery.
2026-10128 — Revision of Applications for Manufacturing and Procurement Quotas
The DEA wants to update how companies apply for permission to make and buy certain controlled drugs and chemicals. These changes will make the rules clearer, help prevent drug shortages, and ensure enough supply for medical and scientific needs. If you’re a manufacturer or involved in this process, get ready to follow new steps and share your thoughts by July 20, 2026.
2026-11572 — Ashley Vermillion, N.P.; Decision and Order
Ashley Vermillion, a nurse practitioner from Maine, lost her DEA registration because she no longer has the legal right to handle controlled substances in her state. She didn’t ask for a hearing, so the DEA moved forward and officially revoked her registration. This means she can’t prescribe or manage controlled drugs anymore, effective immediately.
2026-11416 — Importer of Controlled Substances Application: CalCog Inc.
CalCog Inc. wants to become an official importer of some powerful controlled substances like LSD and 5-MeO-DMT. People and companies involved with these drugs have until July 8, 2026, to share their thoughts or ask for a hearing. This move could shake up the import scene, but no costs or changes happen until the DEA decides.
2026-10380 — Schedules of Controlled Substances: Placement of Diphenidine in Schedule I
The DEA wants to put diphenidine, a drug, into Schedule I, which means it will be treated like the most tightly controlled substances. This change affects anyone who makes, sells, studies, or owns diphenidine, adding strict rules and penalties. You’ve got until June 25, 2026, to share your thoughts before the new rules might kick in.
2026-10253 — Schedules of Controlled Substances: Temporary Placement of 2-Fluorodeschloroketamine in Schedule I
Starting May 22, 2026, the DEA is putting 2-fluorodeschloroketamine (2-FDCK) into Schedule I, meaning it’s now treated like the most dangerous drugs. This affects anyone who makes, sells, or uses it, adding strict rules and serious penalties. The temporary ban lasts two years, giving the government time to decide if it should stay permanent.
Previous / Next Documents
Previous: 2025-13121 — JYA LLC d/b/a Webb's Square Pharmacy; Decision and Order
Webb's Square Pharmacy in Florida lost its DEA license because it gave out controlled medicines without proper prescriptions from July 2021 to March 2024. The pharmacy didn’t respond to the government’s warnings, so their registration was suspended and then revoked to protect public safety. This means they can’t legally handle controlled drugs anymore, effective immediately, impacting their business and customers.
Next: 2025-13125 — Agency Information Collection Activities Under OMB Review
Heads up! The government is reviewing some paperwork rules to make sure they’re not too tricky or costly. If you’re a business or part of a group that fills out government forms, you might see some changes soon. This review helps keep things fair and saves time and money for everyone involved.